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Abstract: Background Nerve‐sparing (NS) surgery was developed to improve postoperative sexual and
potentially urological outcomes after radical prostatectomy (RP). However, it is largely unknown how
NSRP affects health‐related quality of life (HRQoL) including urinary and sexual outcomes in prostate
cancer (PC) survivors 5‐10 years after diagnosis in comparison with Non‐NSRP. Methods The study
population included 382 stage pT2‐T3N0M0 PC survivors 5‐10 years post diagnosis, who were identi-
fied from the multiregional Prostate Cancer Survivorship in Switzerland (PROCAS) study. Briefly, in
2017/2018, PC survivors were identified via six population‐based cancer registries based in both Ger-
man‐ and French‐speaking Switzerland. HRQoL and PC‐specific symptom burden was assessed using
the EORTC QLQ‐C30 and EORTC QLQ‐PR25 questionnaires. Differences in HRQoL outcomes between
survivors treated with NSRP (uni‐ bilateral) and Non‐NSRP were analyzed with multivariable linear
regression adjusted for age, years since diagnosis, cancer stage, comorbidities at diagnosis, and further
therapies, if appropriate. Multiple imputation was performed to minimize the bias due to missing data.
Results Five to ten years after diagnosis, PC survivors treated with NSRP and Non‐NSRP reported
similar symptom burden and comparable HRQoL function scores. The only significant differences were
reported for sexual activity, whereas PC survivors who underwent NSRP reported statistically significant
(P = .031) higher sexual activity than those on Non‐NSRP. NSRP and Non‐NSRP reported similar scores
for urinary symptoms and all other HRQoL outcomes. Conclusions Our results support nerve‐sparing
techniques as an option to improve postoperative sexual, but not urinary outcomes after RP in long‐term
PC survivors.
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Abstract
Background: Nerve-sparing (NS) surgery was developed to improve postopera-
tive sexual and potentially urological outcomes after radical prostatectomy (RP). 
However, it is largely unknown how NSRP affects health-related quality of life 
(HRQoL) including urinary and sexual outcomes in prostate cancer (PC) survivors 
5-10 years after diagnosis in comparison with Non-NSRP.
Methods: The study population included 382 stage pT2-T3N0M0 PC survivors 
5-10  years post diagnosis, who were identified from the multiregional Prostate 
Cancer Survivorship in Switzerland (PROCAS) study. Briefly, in 2017/2018, PC 
survivors were identified via six population-based cancer registries based in both 
German- and French-speaking Switzerland. HRQoL and PC-specific symptom 
burden was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 ques-
tionnaires. Differences in HRQoL outcomes between survivors treated with NSRP 
(uni- & bilateral) and Non-NSRP were analyzed with multivariable linear regression 
adjusted for age, years since diagnosis, cancer stage, comorbidities at diagnosis, and 
further therapies, if appropriate. Multiple imputation was performed to minimize the 
bias due to missing data.
Results: Five to ten years after diagnosis, PC survivors treated with NSRP and Non-
NSRP reported similar symptom burden and comparable HRQoL function scores. 
The only significant differences were reported for sexual activity, whereas PC survi-
vors who underwent NSRP reported statistically significant (P = .031) higher sexual 
activity than those on Non-NSRP. NSRP and Non-NSRP reported similar scores for 
urinary symptoms and all other HRQoL outcomes.
Conclusions: Our results support nerve-sparing techniques as an option to improve 
postoperative sexual, but not urinary outcomes after RP in long-term PC survivors.
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1 |  INTRODUCTION
Prostate Cancer (PC) remains the most frequently diag-
nosed cancer in men in many Western countries with an 
age-adjusted cumulative incidence rate in Switzerland of 
129.6/100,000.1 Over the last decades, PC prognosis has 
substantially improved resulting in a 5-year relative sur-
vival rate of 90% in Switzerland.2 Although radical pros-
tatectomy (RP) is the most common treatment strategy for 
men diagnosed with PC 3 with 88.2 RP/100’000 men in 
Switzerland,1 the survival benefit for PC survivors treated 
with RP compared to other primary management options re-
mains unclear.4–6 For example, an analysis of PC survivors 
in the Swiss canton of Zurich revealed similar relative 1-, 
5-, and 10-year survival rates for PC survivors treated either 
with RP or radiotherapy.7 In addition, RP may have both 
strong acute and long-lasting detrimental effects, notably on 
urinary and sexual functioning.8–11
Nerve-sparing (NS) technique was developed to improve 
postoperative sexual function (SEF) 12 and potentially uri-
nary outcomes after RP. Indeed, higher recovery rates of 
SEF after nerve-sparing RP compared to non-nerve-spar-
ing (Non-NS) RP could be observed up to 24 months.13,14 
However, a positive effect for postoperative urinary out-
comes remains controversial.15,16 For example, a study 
performed at the cantonal hospital Graubünden among 453 
PC patients treated with robot-assisted RP, whereas 265 
patients (58.5%) were operated nerve-sparing, showed that 
planed nerve-sparing was not associated with an improved 
continence rate.17 A systematic review published in 2015 
concluded that preservation of the neurovascular bundles 
improves urinary continence in the first 6  months after 
surgery, but no effect was seen for later time points up to 
5 years after treatment.18
Even though extensive research was performed regard-
ing whether NSRP improves urinary outcomes and SEF 
compared to Non-NSRP in the first time 6-24 months after 
the operation, little attention has been given to long-term 
effects. Also research regarding whether NSRP compared 
to Non-NSRP affects general health-related quality of life 
(HRQoL) remains limited. To the authors’ knowledge, only 
one study from the United States 19 has assessed HRQoL 
domains (physical functioning and mental health) and 
disease-specific symptom burden in PC survivors up to 
10 years after diagnosis either treated with NSRP or Non-
NSRP. In this longitudinal study, PC survivors treated 
with Non-NSRP reported similar declines at 5 years after 
diagnosis in physical functioning, mental health, and uri-
nary continence scores compared to survivors treated with 
NSRP but significantly stronger declines in SEF scores. 
However, no study assessed further HRQoL functions 
and cancer and treatment-related symptom burden beside 
urinary outcomes and SEF in long-term PC survivors. 
Therefore, the objective of our study was to identify differ-
ences and similarities in general HRQoL and PC-specific 
symptom burden by NSRP (uni/bilateral) and Non-NSRP 
in long-term PC survivors.
2 |  MATERIAL AND METHODS
2.1 | Study design and study population
Participants were included from the multiregional Prostate 
Cancer Survivorship in Switzerland (PROCAS) cohort. 
Details of the PROCAS study recruitment and data collec-
tion design have been described elsewhere.20 In short, the 
PROCAS study included 748 long-term PC survivors who 
were diagnosed between 2006 and 2011 and aged 42-75 years 
at diagnosis. They were identified via six population-based 
cancer registries (Cancer Registry Fribourg, Cancer Registry 
Basel, Cancer Registry Graubünden and Glarus, Cancer 
(C071), Division of Clinical Epidemiology 
and Aging Research (C070), German 
Cancer Research Center (DKFZ), Im 
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Registry East Switzerland, Valais Cancer Registry & Cancer 
Registry Zurich and Zug) covering an underlying population 
of 3 456 020 million inhabitants, based in both German and 
French-speaking Switzerland and invited via their referring 
urologists. Data collection was conducted between 2017 
and 2018 by postal questionnaire. Nonrespondents received 
one reminder. Among PC survivors, 8712 fulfilled the in-
clusion criteria for the study (Figure 1). Of them, 1246 PC 
survivors were randomly selected for participation. 1194 
could be contacted and received an invitation. Finally, 748 
returned a completed questionnaire (response rate: 62.2%). 
This analysis was restricted to PC survivors (a) staged pT2-
T3 N0 and M0 (according to the TNM classification system 
published by the American Joint Committee on Cancer have 
been available in the FCD since 200221), (b) treated with RP 
as primary therapy, and (c) recruited from cancer registries 
(Cancer Registry Graubünden and Glarus, Cancer Registry 
East Switzerland, Valais Cancer Registry & Cancer Registry 
Zurich and Zug), which provided information on degree of 
NSRP (N = 382). Our sample was restricted to pT2-T3N0M0 
cases to create a homogenous cohort, because PC patients 
staged pT4 or with cancer in lymph nodes or metastases need 
different treatment strategies.
3 |  STUDY MEASURES
3.1 | HRQoL and PC-specific symptom 
burden
HRQoL and PC-specific symptom burden were assessed once 
(cross-sectional design) with internationally validated instru-
ments: the EORTC QLQ-C30 and the PC-specific module 
QLQ-PR25. The EORTC QLQ-C30 questionnaire consists 
of 30 items, comprising five functioning scales, a global 
health/quality of life (QoL) scale, and nine items/scales on 
symptoms and financial difficulties. The PC-specific EORTC 
QLQ-PR25 questionnaire consists of 25 questions, assessing 
urinary and bowel symptoms, sexual activity, sexual func-
tioning, and hormonal treatment-related symptoms. Scoring 
of all instruments was performed according to the pertinent 
scoring manuals.22,23 High scores on the functioning scales 
and global health/QoL indicate better functioning and bet-
ter health, respectively. For the symptom and financial dif-
ficulty scales, a higher score represents a greater symptom 
burden and financial difficulty. High scores in the EORTC 
QLQ-PR25 represent a greater symptom burden or a better 
sexual functioning and more sexual activity.
F I G U R E  1  Study Flowchart. *For PC 
survivors in the cantons of Basel-Stadt (BS), 
Basel-Landschaft (BL), and Fribourg (FR) 
information on degree of NSRP was not 
available
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3.2 | Demographics, lifestyle, and 
clinical data
Information whether patients were treated with NSRP and 
whether it was uni- or bilateral NSRP were provided by 
the treating urologist, together with the cantonal and re-
gional cancer registries. Assessment whether NSRP was 
performed nerve-sparing was based on the surgeons’ ap-
praisal. Physicians also gave detailed information on other 
treatments, disease progression/ relapse (including biochemi-
cal and clinical recurrence and metastasis after diagnosis of 
primary tumor at time of survey) and other primary tumors. 
Cancer registries provided demographic parameters and clin-
ical information such as date of birth, date of diagnosis and 
cancer stage. Self-reported demographic included education, 
living with partner, working status, weight, height, and na-
tionality. Questionnaires and all other study documents were 
available in German, French, and Italian.
4 |  STATISTICS
For descriptive purposes, we compared Non-NSRP (n = 167) 
vs NSRP (n = 215) by several clinical and sociodemographic 
characteristics. The group NSRP consisted of PC survivors 
treated with both uni- and bilateral NSRP, as these two 
groups did not differ with respect to clinical and sociode-
mographic characteristics (Table S1) and reported similar 
HRQoL outcomes (Tables S2). Additionally, we compared 
uni- and bilateral NSRP with Non-NSRP separately in order 
to determine whether outcomes of unilateral NSRP and Non-
NSRP might be more similar to each another than they were 
to bilateral NSRP.
Adjusted means based on multivariable linear regression 
models were calculated to describe and test for differences in 
HRQoL. Models were adjusted for age at survey, years since 
diagnosis, cancer stage at diagnosis, comorbidities at diag-
nosis, and further therapy (during 1st year after diagnosis) 
if appropriate. Other variables including education, working 
status, nationality, and language were considered as addi-
tional potential confounders, but not included as they did not 
improve the model fit.
To assess the effect of age and disease progression/re-
lapse, we performed sensitivity analysis: (a) excluding all pa-
tients with a disease progressions/relapse and (b) stratifying 
by age using the mean of 72.4 years as cut-off.
Multiple Imputation Chained Equations (MICE) proce-
dure with 25 repetitions was used to reduce possible bias due 
to missing values. MICE is the standard procedure in epidemi-
ological research under the missing-at-random assumption.24 
It has the advantage that missing values are filled multiple 
times “(…) based on the observed values for a given individ-
ual and the relation observed in the data for other participants 
(…)”.25 Therefore, the analyses of the multiple imputed data 
consider the uncertainty in the imputed data, resulting in ac-
curate standard errors.25 Differences in mean HRQoL scores 
larger than 10 points were considered clinically meaningful.26 
A P-value < .05 (two-sided) was considered statistically sig-
nificant. The P-values were not adjusted for multiple testing, 
so the P-values refer to the individual tests rather than a global 
test for differences. All analyses were performed using STATA 
statistical software (Version 15.1).
5 |  RESULTS
Overall, from 382 PC survivors included in this analysis 
56.3%, received NSRP and 43.7% Non-NSRP (Table 1). 
Mean age was 72.4  years and mean time since diagnosis 
was 7.5  years. Participants had mainly Swiss nationality 
and filled-in the German questionnaire. Beside years since 
diagnosis (P  =  .026) and disease progression (P  =  .029), 
clinical and demographic characteristics were comparable 
among PC survivors by treatment strategy. For PC survi-
vors treated with Non-NSRP mean time since diagnosis 
was 7.8  years, whereas it was 7.4  years for PC survivors 
treated with NSRP. Moreover, disease progression/relapse 
was more likely among participants on Non-NSRP (28.8% 
vs 17.7%).
Multiple imputation did not substantially alter the distri-
bution of Non-NSRP and NSRP (Table S3) and their associ-
ation with baseline clinical and demographic characteristics 
(Tables S4) and HRQoL outcomes (Table S5).
5.1 | HRQoL and PC-specific symptom 
burden of PC survivors treated with Non-
NSRP vs NSRP
In general, PC survivors reported excellent functioning and 
good general health/overall quality of life. Adjusted mean 
scores of all functioning scales were comparable between 
PC survivors who have received Non-NSRP and NSRP 
(Figure 2, all P-values > .05).
Fatigue, insomnia and pain were the symptoms with the 
highest reported burden among all PC survivors. However, 
differences in adjusted mean scores between patients 
treated with Non-NSRP and NSRP were small (max. 2.8 
scale points) and not statistically significant (Figure 3, all 
P-values > .05).
PC survivors who underwent NSRP reported statistically 
significant (P =  .031) higher sexual activity (not clinically 
significant different), but similar sexual functioning com-
pared to those who have received Non-NSRP (Figure  4). 
Regarding urinary symptoms and urinary bother no signif-
icant different mean scores were reported.
5420 |   ADAM ET AL.







<70 years 30.4 29.6 31.7
70-74 years 32.2 31.1 33.0
75-79 years 25.1 25.0 25.2
≥80 years 12.3 15.2 10.1
Mean (SD) 72.4 (6.3) 72.9 (6.5) 71.9 (6.3) .236
Education (highest degree)a 
Low 0.8 0.6 0.9
Medium 51.2 50.3 51.8
High 48.0 49.1 47.3 .572
Nationality Swiss (yes) 95.5 96.0 95.2 .752
Language questionnaire
German 94.8 97.0 93.0
French/Italian 5.2 3.0 7.0 .127
Living with partner (yes) 82.3 78.1 85.5 .197
Working at survey (yes) 11.8 10.4 12.9 .54
Body Mass Index
<18.5 0.3 0.6 0.0
18.5-24.9 35.1 31.1 38.0
25.0-29.9 52.0 51.6 51.6
≥30 12.6 16.8 10.4 .212
Cancer stage
pT2N0M0 77.4 72.8 82.0
pT3N0M0 22.6 27.2 18.0 .087
Years since diagnosis
5-6 27.2 22.3 31.0
7-8 46.1 43.8 47.8
9-10 26.7 33.9 21.1
Mean (SD) 7.5 (1.4) 7.8 (1.5) 7.4 (1.5) .026
Disease progression/relapse (yes) 22.0 28.4 17.7 .029
Comorbidities at diagnosis
0 72.4 80.0 66.9
1 19.1 12.2 24.2
≥2 8.5 7.8 8.9 .091
Further therapy (during 1st year after diagnosis)
External-beam radiation therapy 6.6 7.8 5.6 .584
Hormone therapy 4.0 4.3 3.7 .850
Abbreviation: Col, Column.
aEducation: Low (no or primary school); Medium (lower general secondary education or vocational training); High (pre-university education, high vocational training, 
university). 
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Neither differences in urinary symptoms (n  =  132), 
urinary bother (n = 37) nor sexual activity (n = 131) and 
sexual function (n = 73) were observed when comparing 
HRQoL and PC-specific symptom burden of PC survivors 
treated with unilateral NSRP vs bilateral NSRP (Table S2). 
When unilateral and bilateral NSRP were compared to 
Non-NSRP separately, results showed a similar pattern, in-
dicating that unilateral NSRP outcomes were not more sim-
ilar to Non-NSRP than to bilateral NSRP (data not shown).
Restriction to long-term PC survivors without disease 
progression/relapse did not substantially alter the pattern of 
our findings (data not shown). Furthermore, the pattern of 
F I G U R E  2  Adjusted mean scores of EORTC QLQ-C30 HRQoL scales of PC survivors by nerve-sparing status (after multiple imputation of 
missing values). A high score represents a high/healthy level of functioning/high QoL. Mean scores were adjusted for age at survey, years since 
diagnosis, cancer stage, comorbidities at diagnosis, and further therapy if appropriate. I bars represent ± standard errors; all P-values > .05
F I G U R E  3  Adjusted mean of EORTC QLQ-C30 symptom scales of PC survivors by nerve-sparing status (after multiple imputation of 
missing values). A high score represents a high symptom burden. Mean scores were adjusted for age at survey, years since diagnosis, cancer stage, 
comorbidities at diagnosis, and further therapy if appropriate. I bars represent ± standard errors; all P-values > .05
F I G U R E  4  Adjusted mean of EORTC PR25 scales of PC survivors by nerve-sparing status (after multiple imputation of missing values).A 
high score represents higher symptom burden or higher sexual activity/ better sexual functioning. Mean scores were adjusted for age at survey, 
years since diagnosis, cancer stage, comorbidities at diagnosis and further therapy if appropriate.1 smaller sample size as questions regarding these 
functions were conditional—urinary bother (n = 104) & sexual functioning (n = 183)I bars represent ± standard errors; all P-values > .05 if not 
indicated otherwise
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our findings was similar in age-stratified analyses. However, 
younger long-term survivors (<72.4  years of age) reported 
higher HRQoL functioning scores and lower symptom bur-
den scores (Table S6 & Table S7). Even though younger 
long-term PC survivors treated with NSRP reported a 6.3-
point higher score for sexual activity, this difference was 
statistically significant (P = .043) and clinically meaningful 
only in older long-term PC survivors.
6 |  DISCUSSION
Given the increasing numbers of long-term PC survivors,27 it 
is imperative to understand whether treatment modalities such 
as NSRP may result in long-lasting health benefits including 
better HRQoL and lower PC-specific symptom burden. This 
population-based study suggests, however, that HRQoL and 
symptom burden in PC survivors 5-10 years after diagnosis 
of localized PC in general does not vary according to type of 
surgery (NSRP versus Non-NSRP) except for the finding that 
PC survivors who underwent NSRP were significantly more 
sexually active than those treated with Non-NSRP.
In general, the results from our cross-sectional survey con-
firm and extend the results of the longitudinal survey based 
on the CaPSURE registry.19 In addition to the results from 
the CaPSURE registry which described differences in SEF 
but comparable physical and mental health in PC survivors 
after NSRP and Non-NSRP, there appears to be no further 
differences between the two treatment groups with respect 
to global health status, role, emotional, cognitive, and social 
functioning as well as burden of fatigue, insomnia, dyspnoea, 
constipation and pain according to our study. The result that 
no differences were observed in any non-PC-specific HRQoL 
and symptom burden domains is in line with previous studies, 
which reported little to no difference in HRQoL of long-term 
PC survivors between treatment modalities 9 or in comparison 
with the general population.11 An explanation for this finding 
might be the response shift phenomenon, which results in a 
change in perception of burden threshold28,29 after a cancer 
diagnosis. Even though long-term PC survivors treated with 
Non-NSRP suffer from worse SEF than survivors treated 
with NSRP, there is no impact on other HRQoL domains.
Previous studies have reported that NSRP improves post-
operative sexual function up to five13,14,30 and 10 years after 
diagnosis19 compared to Non-NSRP. In our study, no signif-
icant differences for SEF were reported, but patients treated 
with NSRP scored significantly higher on all sexual activity 
scales. The discrepancy between our results and the afore-
mentioned studies is potentially based on the usage of dif-
ferent instruments to assess PC-specific symptom burden. 
In this study, the EORTC-PR25 questionnaire was used, 
whereas the other studies used the UCLA-PCI and the EPIC-
26 questionnaire. In the EORTC-PR25, sexual activity is 
measured with two questions, which are asking about sex-
ual interest and frequency of sexual activity. Only patients 
who were sexually active (183/382) answered the additional 
questions on the ability to have an erection and orgasm, and 
sexual desire,23 which corresponds to the SEF domain. In 
contrast, all these items including level of sexual activity 
are part of the SEF domain in the other two instruments.31 
Therefore, results regarding SEF from studies using different 
QoL instruments are not directly comparable. Nevertheless, 
our finding that NSRP results in favourable sexual function 
even 5-10 years after diagnosis has potential clinical impli-
cations, even though the difference was small (not clinically 
meaningful), indicating that the impact may be less import-
ant for the individual. However, as the number of long-term 
PC survivors is substantially growing,32 a large number of 
individuals are affected. Moreover, most PC survivors have 
very good survival perspectives and live with their partners. 
Therefore, we believe that our results might have an impact 
on the treatment decision-making process.
In this context, the focus should be on older long-term PC 
survivors. Even though, as indicated in an analysis of long-
term PC survivors in Germany,11 HRQoL scores are probably 
lower and symptom burden scores higher in older long-term 
PC survivors; the differences in sexual activity in older PC 
survivors were not only statistically significant but also larger 
(clinically meaningful) than in younger survivors. Thus, the 
chances to preserve sexual activity should also play a role in 
elderly patient groups when deciding for a treatment strategy. 
However, these results need to be interpreted with caution 
due to the small sample size.
The lack of differences with respect to long-term urinary 
symptoms and urinary bother might be surprising, but our re-
sults are similar to another study performed in Switzerland,16 
even though studies differ methodologically. The latter study 
continuously assessed and compared urinary incontinence 
over a 10-year period in PC survivors either treated with 
NSRP or Non-NSRP. This study was conducted in a canton, 
which was not part of this study, and adjusted its models for 
factors (such as PC volume, clinical risk group, positive mar-
gins, and preoperative urinary incontinence score and PSA-
values), which were not assessed in our study. Beside those 
differences, the similarity of the results supports the conclu-
sion of the other study, stating that NSRP should not be con-
ducted with the primary aim to improve urinary outcomes.
To our knowledge, this is the first study performed in 
Europe which compared HRQoL and PC-specific symp-
tom burden according to NS surgery in long-term PC 
survivors, using a multiregional-based design, including 
patient recruitment via multiple population-based cancer 
registries in two different language regions. Beside these 
strengths, there are limitations which need to be discussed. 
For example, not in all study regions, information was 
available whether participants received NSRP. Therefore, 
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participants of two study regions were excluded from this 
analysis. Moreover, although we corrected our models for 
a range of clinical and sociodemographic variables, we did 
not have all information such as clinical risk group, the 
degree of nerve-sparing, urinary outcome scores and most 
importantly baseline SEF, which might have influenced ei-
ther the treatment choice or the outcome. Additionally, we 
were not able to identify trends over time, as HRQoL in the 
PROCAS study was assessed only once for each partici-
pant. Other studies indicated that HRQoL of PC survivors 
appears to be lower during and shortly after treatment, but 
to improve and stabilize thereafter.8,33,34 However, due to 
the cross-sectional design of our study, causality between 
NSRP and better sexual outcomes cannot be established. 
Finally, information on whether RP was performed open 
or robotic-assisted was not assessed in the study, what 
might also influence the generalizability of our results even 
though these two techniques yielded similar functional out-
comes in short-term PC survivors as seen in randomized 
controlled trials.35
7 |  CONCLUSION
In conclusion, NSRP was generally associated with compa-
rable long-term HRQoL outcomes but higher sexual activity 
scores when compared to Non-NSRP. Our results support 
nerve-sparing techniques as an option to improve post-opera-
tive sexual but not urinary outcomes after RP in PC survivors.
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